79227609-ce40-4cf9-a9eb-16732cc2bfc5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 86.839151266256
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- E2F_TARGETS+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- G2M_CHECKPOINT+0.240
- WNT_BETA_CATENIN_SIGNALING+0.230
- MYC_TARGETS_V1+0.180
- MITOTIC_SPINDLE+0.160
- DNA_REPAIR+0.150
- HEDGEHOG_SIGNALING+0.100
- OXIDATIVE_PHOSPHORYLATION+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- ALLOGRAFT_REJECTION-0.400
- INFLAMMATORY_RESPONSE-0.390
- COMPLEMENT-0.370
- INTERFERON_GAMMA_RESPONSE-0.370
- ANDROGEN_RESPONSE-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- UV_RESPONSE_DN-0.330
- IL2_STAT5_SIGNALING-0.310
- KRAS_SIGNALING_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03678 | — | cohortSQ1 | 0.882 |
| 2 | SRR2932822 | — | — | 0.877 |
| 3 | 20050169.TNBC | — | E | 0.870 |
| 4 | SRR25043617 | — | — | 0.867 |
| 5 | cf37eb41-0595-4a82-a65b-3058902a48d4 | — | — | 0.864 |
| 6 | ERR2208888 | — | — | 0.861 |
| 7 | SRR6013540 | — | cohortSQ2 | 0.858 |
| 8 | BS_K3ER45RV | medulloblastoma | — | 0.857 |
| 9 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.857 |
| 10 | C3N-01025 | — | cohortSQ2 | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |